Athenex, Inc. (ATNX)

Market Cap	31.32M
Revenue (ttm)	119.71M
Net Income (ttm)	-173.63M
Shares Out	139.47M
EPS (ttm)	-1.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	598,230
Open	0.205
Previous Close	0.199
Day's Range	0.19 - 0.205
52-Week Range	0.162 - 1.74
Beta	1.10
Analysts	Buy
Price Target	2.21 (+1,039.2%)
Earnings Date	Nov 3, 2022

About ATNX

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It...

• Industry: Biotechnology
• IPO Date: Jun 14, 2017
• CEO: Johnson Lau
• Employees: 652
• Stock Exchange: NASDAQ
• Ticker Symbol: ATNX

Financial Performance

In 2021, Athenex's revenue was $120.18 million, a decrease of -16.77% compared to the previous year's $144.39 million. Losses were -$199.77 million, 36.7% more than in 2020.

Analyst Forecast

According to 9 analysts, the average rating for ATNX stock is "Buy." The 12-month stock price forecast is 2.21, which is an increase of 1,039.18% from the latest price.

Price Target

$2.21

(1,039.18% upside)

Analyst Consensus: Buy